A peer-reviewed study published in JMIR Formative Research found that active subscribers on Second Natures semaglutide-supported programme lost an average of 19.1% of their body weight at 12 months, with 77.7% achieving at least 10% weight loss
Patients experiencing urinary changes during GLP-1 therapy can implement several practical strategies to manage symptoms whilst continuing beneficial treatment
A study has analyzed how plasma DPP-4 activity and levels of soluble DPP-4 correlate with inflammatory markers (C-reactive protein [CRP], IL-6, TNF-, and monocyte chemoattractant protein-1 [MCP-1]) in a subset of patients with T2DM treated with sitagliptin for 12 months as part of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS, 26)
For instance, a child of parents with brown eyes may have blue eyes if their grandparents have blue eyes
Retatrutide is a triple agonist acting on GIP, GLP-1, and glucagon receptors
Understanding these differences helps patients and healthcare providers verify medication authenticity and proper handling
